Ocular Therapeutix pulled in a Series D round of financing from Baxter Ventures, giving Baxter a minority equity stake. The Bedford, MA-based Ocular will use the undisclosed funding amount to further develop its sustained-release drug programs, including glaucoma treatments and steroids for postoperative inflammation and pain, the company said. Ocular's treatments derive from its hydrogel delivery platform, which also forms the basis of its ReSure Sealant, expected to gain FDA approval soon. Release